ASPREE-D: Aspirin for the prevention of depression in the elderly
dc.contributor.author | Berk, M. | |
dc.contributor.author | Woods, R. | |
dc.contributor.author | Nelson, M. | |
dc.contributor.author | Shah, R. | |
dc.contributor.author | Reid, Christopher | |
dc.contributor.author | Storey, E. | |
dc.contributor.author | Fitzgerald, S. | |
dc.contributor.author | Lockery, J. | |
dc.contributor.author | Wolfe, R. | |
dc.contributor.author | Mohebbi, M. | |
dc.contributor.author | Murray, A. | |
dc.contributor.author | Kirpach, B. | |
dc.contributor.author | Grimm, R. | |
dc.contributor.author | McNeil, J. | |
dc.date.accessioned | 2017-01-30T12:15:25Z | |
dc.date.available | 2017-01-30T12:15:25Z | |
dc.date.created | 2016-09-27T09:52:11Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Berk, M. and Woods, R. and Nelson, M. and Shah, R. and Reid, C. and Storey, E. and Fitzgerald, S. et al. 2016. ASPREE-D: Aspirin for the prevention of depression in the elderly. International Psychogeriatrics. 28 (10): pp. 1741-1748. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/19735 | |
dc.identifier.doi | 10.1017/S104161021600079X | |
dc.description.abstract |
Copyright © International Psychogeriatric Association 2016. Background:: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention. Method:: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression. Results:: This paper presents the rationale for the study and presents a summary of the study design. Conclusions:: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression. | |
dc.publisher | Cambridge University Press | |
dc.title | ASPREE-D: Aspirin for the prevention of depression in the elderly | |
dc.type | Journal Article | |
dcterms.source.startPage | 1 | |
dcterms.source.endPage | 8 | |
dcterms.source.issn | 1041-6102 | |
dcterms.source.title | International Psychogeriatrics | |
curtin.note |
This version of the article has been accepted for publication and will appear in a revised form subsequent to peer review and / or editorial input | |
curtin.department | Department of Health Policy and Management | |
curtin.accessStatus | Open access |